? Immunobiology Program The Immunobiology Program (IMB) serves as a rich resource for the Abramson Cancer Center (ACC) in advancing an understanding of immunobiology and immunotherapy of cancer. The Program aims to: 1) Understand the fundamental aspects of immune biology, including leukocyte activation, differentiation, inactivation, and transformation as these relate to cancer; 2) Forge a comprehensive understanding of tumor immune surveillance using state-of-the art in vitro, animal model, and human experimental systems; and 3) Guide translation of novel clinical strategies for immunotherapy of cancer by leading or collaborating on human clinical trials. Established in 1974, this Research Program received ?Exceptional? merit at the time of the last CCSG renewal application. The Program co-Leaders (PLs) are Warren Pear, MD, PhD, an expert in the molecular biology of leukocyte development and malignant transformation and E. John Wherry, PhD, a leader in tumor immunology, immune exhaustion and immunotherapy. Drs. Pear and Wherry are experienced, NCI- funded investigators who are highly collaborative and whose research interests span the realm of basic and translational science. There are 39 Program members from nine departments and three schools with long- standing intra- and inter-Programmatic collaborations spanning the basic, clinical, and population science Programs. Members include international leaders in basic immunology, tumor immunobiology and translational immunotherapy who have driven landmark breakthroughs such as molecularly defining T cell exhaustion, dissecting the biologic response to checkpoint inhibition, and developing CAR T cells that revolutionized cellular therapy for cancer. IMB collaborates extensively with other Programs for clinical translation and biomarker discovery. For example, CART19 T cells were designed in IMB then translated to the clinic with members of the Hematologic Malignancies and Pediatric Oncology Programs in studies that led to two FDA- approved indications. The PLs facilitate interactions through multiple weekly seminars and meetings, promotion of collaborative grants and projects, two annual research retreats, pilot project grants, and training programs. During the current project period, PLs recruited 11 new Full members, expanded important forums, facilitated new collaborative grants, initiated new ACC-wide initiatives, and were actively involved in decisions regarding new and existing Shared Resources. Currently, Program members have $24.2M in research grant funding (annual direct costs), of which $15.1M is peer-reviewed and $4.1M is NCI-funded. The Program holds 38 R01-equivalents. During the current project period, Program members published 468 cancer-related publications, many of which are in top journals in the field. Of these, 19% are intra-Programmatic, 32% are inter-Programmatic, and 72% are multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088742
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Morrison, Alexander H; Byrne, Katelyn T; Vonderheide, Robert H (2018) Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 4:418-428
Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Buljan, Vlado A; Graeber, Manuel B; Holsinger, R M Damian et al. (2018) Calcium-axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes. J Biol Phys 44:53-80

Showing the most recent 10 out of 1047 publications